Technical Data
A2299-98P
APRIL, ED, Blocking Peptide (a Proliferation Inducing Ligand, TALL-2, TNF and ApoL-related Leukocyte-expressed Ligand 2, TRDL-1a, TNF-related Death Ligand 1a, TNFSF13)
50ug
Molecular Biology Storage: -20CShipping: Blue Ice
Control Peptide for A2299-98.

Members in the TNF superfamily regulate immune responses and induce apoptosis. A novel member in the TNF family was recently identi ed by several groups and designated APRIL (for a proliferation-inducing ligand), TALL-2 (for TNF-and ApoL-related Leukocyte-expressed Ligand 2), and TRDL-1a (for TNF related death ligand 1a) in human and mouse (1-4). Two receptors for APRIL were recently identi ed and designated TACI and BCMA (5-7). APRIL stimulates B and T cell proliferation, triggers humoral immune responses, activates NF-kB and induces cell death (1-7). APRIL and its close relative of BlyS and their receptors BCMA and TACI are involved in diseases of autoimmunity and cancer (8,9).

Applications:
Suitable for use in ELISA, Antibody Blocking. Not suitable for use in Western Blot due to low molecular weight. Other applications not tested.

Recommended Dilution:
Antibody Blocking: Equal volume peptide to antibody (AA99-98) for 30 minutes at RT.
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. For long-term storage, store at -20C. Aliquots are stable for at least 6 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
Source: Synthetic peptide
Purity: Purified 60-70%
Concentration: ~0.2mg/ml
Form: Supplied as a lyophilized powder.
Specificity: Synthetic peptide corresponding to aa67-79 (GTGGPSQNGEGYP) of human APRIL (1-3).

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Hahne, M., Kataoka, T., Schroter, M., et al., APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J. Exp. Med.188(6): 1185-90 (1998). 2. Shu, H.B., Hu, W.H., Johnson, H., TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J. Leukoc. Biol. 65(5): 680-3 (1999). 3. Kelly, K., Manos, E., Jensen, G., et al., APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death. Cancer Res. 60(4): 1021-7 (2000). 4. Yu, G., Boone, T., Delaney, J., et al., APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity. Nat. Immunol. 1(3): 252-6 (2000). 5. Wu, Y., Bressette, D., Carrell, J.A., et al. Tumor necrosis factor (TNF) receptor superfamily member TACI is a high af nity receptor for TNF family members APRIL and BLyS. J. Biol. Chem. 275(45): 35478-85 (2000). 6. Marsters, S.A., Yan, M., Pitti, R.M., et al., Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr. Biol. 10(13): 785-8 (2000). 7. Rennert, P., Schneider, P., Cachero, T.G., et al., A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J. Exp. Med. 192(11): 1677-84 (2000). 8. Gross, J.A., Johnston, J., Mudri, S., et al., TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404: 995-9 (2000). 9. Ware, C.F., APRIL and BAFF connect autoimmunity and cancer. J. Exp, Med. 192(11): F35-8 (2000).

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.